Cefprozil (Cefzil)

08/01/1987 - "BMY-28100 was also more potent against infections of H. "
12/01/1992 - "[Clinical studies on cefprozil granules in pediatric skin soft tissues infections]."
06/01/1992 - "Clinical trials of cefprozil for treatment of skin and skin-structure infections: review."
03/01/1993 - "The low-rate of gastrointestinal and dermatologic side effects associated with cefprozil administration suggest that it may have a significant role in the management of patients with these infections. "
11/01/1992 - "Cefprozil (CFPZ, BMY-28100) granule preparation was studied for pharmacokinetic, bacteriological and clinical aspects in the pediatric infections. "

08/01/1993 - "Cefprozil can be considered a safe and reliable drug for the treatment of streptococcal pharyngitis in children."
10/01/1994 - "Four multicenter randomized clinical trials were conducted to compare the clinical efficacy and safety of cefprozil administered once or twice a day for the treatment of mild to moderate GABHS tonsillitis and pharyngitis. "
05/01/1993 - "The cefprozil concentrations in either the tonsillar or the adenoidal tissue at both dose levels over 3.17 h after dosing are much higher than the MICs for common pathogens which cause pharyngitis or tonsillitis."
06/01/1992 - "Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials."
06/01/1991 - "Cefprozil (500 mg once daily) was compared to cefaclor (250 mg three times daily) in an open, randomized, comparative trial for the treatment of acute group A beta-hemolytic streptococcal pharyngitis. "

10/01/1991 - "Cefprozil, 500 mg once daily, appears to be an appropriate alternative for the treatment of acute, uncomplicated urinary tract infections."
11/01/1995 - "The results of this in vitro study indicate that oral administration of cefprozil might be efficacious in the treatment of community-acquired cutaneous, respiratory and urinary tract infections."
02/01/2004 - "After acute urinary tract infections (UTIs) were treated, the patients were divided into 3 groups randomly and TMP/SMZ was given to 21 patients, cephadroxil was given to 25 patients and cefprozil was given to 34 patients for 3 months--one dose at night. "
02/01/2004 - "Comparison of trimethoprim-sulfamethoxazole, cephadroxil and cefprozil as prophylaxis for recurrent urinary tract infections in children."
03/01/1992 - "Cefprozil is a new oral cephalosporin with an in vitro spectrum of activity that includes the pathogens most commonly associated with acute and uncomplicated urinary tract infections (UTIs). "

10/01/1994 - "Four multicenter randomized clinical trials were conducted to compare the clinical efficacy and safety of cefprozil administered once or twice a day for the treatment of mild to moderate GABHS tonsillitis and pharyngitis. "
05/01/1993 - "The cefprozil concentrations in either the tonsillar or the adenoidal tissue at both dose levels over 3.17 h after dosing are much higher than the MICs for common pathogens which cause pharyngitis or tonsillitis."
06/01/1992 - "Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials."
11/01/2001 - "The bacteriologic eradication rate was significantly greater with cefprozil compared with erythromycin in children with pharyngitis/tonsillitis. "
02/01/1993 - "The clinical efficacy of cefprozil is similar to that of cefaclor in patients with tonsillitis or pharyngitis but the bacteriological efficacy of cefprozil is significantly greater than that of cefaclor. "

02/01/1998 - "In conclusion, cefprozil demonstrated excellent in vitro activity against bacterial species responsible for respiratory infections in São Paulo."
10/01/1994 - "Cefprozil was evaluated in four multicentre comparative studies in the treatment of acute respiratory tract infections. "
06/01/1992 - "Review of the experience with cefprozil for the treatment of lower respiratory tract infections."
06/01/1987 - "By virtue of its in vitro spectrum, BMY-28100 can be considered a potentially useful agent for treatment of respiratory tract infections."
02/01/1998 - "Evaluation of the in vitro Activity of Cefprozil Relative to Other Oral Antimicrobial Agents Against Bacteria in Clinical Specimens from Patients in São Paulo With Respiratory Tract Infections."